Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DB8V4Z
|
|||
| Drug Name |
NYX-458
|
|||
| Synonyms |
Nevadistinel; YYL9TO6TW2; NEVADISTINEL [USAN]; SCHEMBL19850602; NYX-458; NYX-3054; HY-156626; CS-0886462; (4S)-2-[(4-Methoxyphenyl)methyl]-2,7-diazaspiro[3.5]nonane-1,6-dione; 2,7-Diazaspiro[3.5]nonane-1,6-dione, 2-[(4-methoxyphenyl)methyl]-, (4S)-; 2181816-92-0
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Parkinson disease [ICD-11: 8A00.0; ICD-10: F02.3, G20; ICD-9: 332] | Phase 2 | [1] | |
| Company |
Aptinyx
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H18N2O3
|
|||
| Canonical SMILES |
COC1=CC=C(C=C1)CN2CC3(C2=O)CCNC(=O)C3
|
|||
| InChI |
InChI=1S/C15H18N2O3/c1-20-12-4-2-11(3-5-12)9-17-10-15(14(17)19)6-7-16-13(18)8-15/h2-5H,6-10H2,1H3,(H,16,18)/t15-/m0/s1
|
|||
| InChIKey |
HMFZRGIXXDQHFG-HNNXBMFYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | N-methyl-D-aspartate receptor (NMDAR) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04148391) A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Associated With Parkinson's Disease or Prodromal or Manifest Lewy Body Dementia. U.S.National Institutes of Health. | |||
| REF 2 | NYX-458 Improves Cognitive Performance in a Primate Parkinson's Disease Model. Mov Disord. 2020 Apr;35(4):640-649. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.